The goals of this study were to (1) explore Vav3 as a novel therapeutic target for human prostate cancer, (2) define the biological effects of si-Vav3 when combined with docetaxel in human prostate cancer cells in culture and experimental animal models, and (3) characterize the downstream signaling pathways of Vav3 in human prostate cancer cells. Here, VAV3 is linked to prostate carcinoma.